Neuralstem receives FDA nod to advance MDD compound to Phase Ib
NSI-189 is the lead compound in Neuralstem’s neuroregenerative small molecule drug platform, indicated to treat psychiatric disorders such as Alzheimer’s disease, anxiety, bipolar disorder and post traumatic stress
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.